Showing 4441-4450 of 5646 results for "".
- Johnson & Johnson Vision Expands “Sight For Kids” Program and Unveils “Vision for Good” Community Impact Reporthttps://modernod.com/news/johnson-johnson-vision-expands-sight-for-kids-program-and-unveils-vision-for-good-community-impact-report/2479256/Johnson & Johnson Vision announced the expansion of nonprofit program
- Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-fda-filing-acceptance-for-xipere/2479252/Bausch Health Companies and Bausch + Lomb, along with Clearside Biomedical, announced that the FDA has accepted the resubmitted new drug application for Xipere (triamcinolone acetonide suprachoroidal injectable suspension). FDA determined that the filing is a Class 2 resubmission and therefore as
- iHealthScreen Announces CE Certification for iPredict Automated AI Systemhttps://modernod.com/news/ihealthscreen-announces-ce-mark-for-ipredict-automated-ai-system-for-early-diagnosis-of-dr-amd-and-glaucoma-suspect/2479244/iHealthScreen announced that it is the first company in the US to receive a CE certification for simultaneous diagnosis of diabetic retinopathy (DR), age related macular degeneration (AMD), and glaucoma suspect screening, according to a company news release. Using the iPredict System,
- Why Can’t Americans Buy Contact Lenses From Vending Machines?https://modernod.com/news/why-cant-americans-buy-contact-lenses-from-vending-machines/2479238/A recent report in The Federalist details the ability to purchase contact lenses throughout most of Europe versus the United States, and the role regulatory agencies have in wh
- Heru Series A Funding Accelerates Cloud and AI-Enabled Wearable Vision Diagnosis and Therapyhttps://modernod.com/news/heru-series-a-funding-accelerates-cloud-and-ai-enabled-wearable-vision-diagnosis-and-therapy/2479231/Heru, developer of wearable AI-powered vision diagnostics and augmentation software, closed its Series A financing of $30 million to advance the company’s eye diagnostic and vision correction technology platform. Originating as a spinout from Bascom Palmer Eye Institute, the Series A follo
- Alcon Data Highlights Benefits of Specific AcrySof Modelshttps://modernod.com/news/alcon-data-highlights-benefits-of-specific-acrysof-models/2479232/Alcon has announced the publication of the National Ophthalmology Database (NOD) audit by The Royal College of Ophthalmologists (RCOphth), which collects data on cataract surgery performed in England, Wales and Guerns
- MedOne Surgical Receives FDA Clearance for its MicroDose Injectorhttps://modernod.com/news/medone-surgical-receives-fda-clearance-for-its-microdose-injector/2479227/MedOne Surgical announced the FDA 510(k) clearance of its MicroDose Injector device for low volume ophthalmic injections into the subretinal space. The pneumatically driven syringe system allows the surgeon to utilize a pneumatic air source, such as a vitrectomy system, to deliver a low volume in
- Bio-Techne and Narayana Nethralaya Collaborate On the Use of Ella for Ophthalmic Disorder Diagnostic Applicationshttps://modernod.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-qualit
- Three Companies Combine to Form Corza Medicalhttps://modernod.com/news/three-companies-combine-to-form-corza-medical/2479217/Corza Medical, a provider of surgical products and technologies, was formed after uniting Surgical Specialties Corporation, Caliber Ophthalmics, and the TachoSil hemostatic patch device. &
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st